Carta A, Briguglio I, Piras S, Corona P, Ibba R, Laurini E, Fermeglia M, Pricl S, Desideri N, Atzori E M, La Colla P, Collu G, Delogu I, Loddo R
Dipartimento di Chimica e Farmacia, Università degli Studi di Sassari, via Muroni 23A, 07100 Sassari, SS, Italy.
Dipartimento di Chimica e Farmacia, Università degli Studi di Sassari, via Muroni 23A, 07100 Sassari, SS, Italy.
Eur J Med Chem. 2016 Jul 19;117:321-34. doi: 10.1016/j.ejmech.2016.03.080. Epub 2016 Apr 8.
In this work, we present and discuss a comprehensive set of both newly and previously synthesized compounds belonging to 5 distinct molecular classes of linear aromatic N-polycyclic systems that efficiently inhibits bovine viral diarrhea virus (BVDV) infection. A coupled in silico/in vitro investigation was employed to formulate a molecular rationale explaining the notable affinity of all molecules to BVDV RNA dependent RNA polymerase (RdRp) NS5B. We initially developed a three-dimensional common-feature pharmacophore model according to which two hydrogen bond acceptors and one hydrophobic aromatic feature are shared by all molecular series in binding the viral polymerase. The pharmacophoric information was used to retrieve a putative binding site on the surface of the BVDV RdRp and to guide compound docking within the protein binding site. The affinity of all compounds towards the enzyme was scored via molecular dynamics-based simulations, showing high correlation with in vitro EC50 data. The determination of the interaction spectra of the protein residues involved in inhibitor binding highlighted amino acids R295 and Y674 as the two fundamental H-bond donors, while two hydrophobic cavities HC1 (residues A221, I261, I287, and Y289) and HC2 (residues V216, Y303, V306, K307, P408, and A412) fulfill the third pharmacophoric requirement. Three RdRp (K263, R295 and Y674) residues critical for drug binding were selected and mutagenized, both in silico and in vitro, into alanine, and the affinity of a set of selected compounds towards the mutant RdRp isoforms was determined accordingly. The agreement between predicted and experimental data confirmed the proposed common molecular rationale shared by molecules characterized by different chemical scaffolds in binding to the BVDV RdRp, ultimately yielding compound 6b (EC50 = 0.3 μM; IC50 = 0.48 μM) as a new, potent inhibitor of this Pestivirus.
在本研究中,我们展示并讨论了一组全面的新合成和先前合成的化合物,这些化合物属于5种不同分子类别的线性芳香族N - 多环系统,能有效抑制牛病毒性腹泻病毒(BVDV)感染。采用计算机模拟和体外实验相结合的研究方法,构建了一个分子理论,以解释所有分子对BVDV RNA依赖性RNA聚合酶(RdRp)NS5B的显著亲和力。我们首先开发了一个三维共同特征药效团模型,据此所有分子系列在结合病毒聚合酶时共享两个氢键受体和一个疏水芳香特征。药效团信息用于检索BVDV RdRp表面的假定结合位点,并指导化合物在蛋白质结合位点内的对接。通过基于分子动力学的模拟对所有化合物与该酶的亲和力进行评分,结果显示与体外EC50数据高度相关。对参与抑制剂结合的蛋白质残基相互作用谱的测定表明,氨基酸R295和Y674是两个基本的氢键供体,而两个疏水腔HC1(残基A221、I261、I287和Y289)和HC2(残基V216、Y303、V306、K307、P408和A412)满足第三个药效团要求。选择了三个对药物结合至关重要的RdRp残基(K263、R295和Y674),在计算机模拟和体外实验中都将其突变为丙氨酸,并相应地测定了一组选定化合物对突变型RdRp异构体的亲和力。预测数据与实验数据的一致性证实了具有不同化学支架的分子在结合BVDV RdRp时共享的共同分子理论,最终得到化合物6b(EC50 = 0.3 μM;IC50 = 0.48 μM),它是这种瘟病毒的一种新型强效抑制剂。